Outcomes of kidney transplants for children with kidney failure related to ANCA-associated vasculitis (AAV) are comparable to outcomes of…
Articles by Marisa Wexler, MS
The case of a man in Saudi Arabia with granulomatosis with polyangiitis (GPA), a form of ANCA-associated vasculitis, highlights…
A committee of the European Medicines Agency has recommended approving Tavneos (avacopan) as an add-on therapy for adults with…
A new classification system, based on the underlying cause of disease, may be necessary to better understand ANCA-associated vasculitis…
A reduced dosage of rituximab maintenance therapy may be effective at preventing relapses among people with ANCA-associated vasculitis (AAV),…
Treatment with ChemoCentryx’s investigational therapy avacopan can improve kidney function in people with ANCA-associated vasculitis to…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
The antibody rituximab is a good alternative to cyclophosphamide for inducing remission in people with ANCA-associated vasculitis (AAV), and…
Use of avacopan can increase remission rates and improve kidney function in people with ANCA-associated vasculitis (AAV), while…
The risk factors that predict serious infections in people with ANCA-associated vasculitis (AAV) vary with time, a study found.